It has been known in the cannabis community for a long time now that epilepsy can be controlled with high CBD low THC cannabis, so it’s good to hear that the research will start. A story in LeafScience are covering the newest developments
While a large body of anecdotal and laboratory evidence points to cannabis as an effective treatment for epilepsy, research in humans is just beginning to catch up.
On Wednesday, GW Pharmaceuticals – the UK-based company behind the natural cannabis spray Sativex – announced the start of the first round of clinical trials of a new cannabis treatment for epilepsy.
Their latest animal study – which appears in the October issue of the British Journal of Pharmacology – showed positive results with two chemicals derived from cannabis: Cannabidiol (CBD) and cannabidivarin (CBDV).
In July, Dr. Orrin Devinsky, Director of the Comprehensive Epilepsy Center at New York University, told the Toronto Star that he had just received FDA approval for a clinical trial of CBD in children with epilepsy.
“I’ve spoken with these parents, and I think they’re solid, good, loving parents, who’ve had very good experiences.”
According to Dr. Devinsky, if results from animal studies are confirmed and there are no setbacks, CBD could be approved in the U.S. in two to three years.